{"id":71409,"date":"2026-05-20T09:18:16","date_gmt":"2026-05-20T09:18:16","guid":{"rendered":"https:\/\/medsbase.com\/l-carnitine\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"l-carnitine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/l-carnitine\/","title":{"rendered":"L-Carnitina (Levocarnitina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 L-Carnitina?<\/h3>\n<p style=\"margin: 0;\"><strong>L-Carnitina<\/strong> (levocarnitina; (3R)-3-hidroxi-4-(trimetilam\u00f4nio)butanoato) \u00e9 um pequeno derivado de amino\u00e1cido quatern\u00e1rio de am\u00f4nio \u2014 <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em> \u2014 that functions as the essential carrier molecule for transporting long-chain fatty acids across the mitochondrial inner membrane for \u03b2-oxidation. It is endogenously biosynthesised from L-lysine and L-methionine and is concentrated in skeletal muscle, heart, and liver. L-Carnitine is studied across mitochondrial-function studies, fat-oxidation physiology, insulin-sensitivity models, cardiovascular studies, neuroprotection (Alzheimer \/ autism in-vitro work), exercise physiology, and sperm-motility studies. Supplied in 600 mg and 1200 mg vials as levocarnitine USP-grade zwitterion for clinical studies use only. Stocked in our peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> as a complementary mitochondrial \/ metabolic support-injectable.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">541-15-1 (sal interno de L-carnitina \/ zwitteri\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Derivado de amino\u00e1cido quatern\u00e1rio de am\u00f4nio (<em>n\u00e3o \u00e9 um pept\u00eddeo<\/em>); o enanti\u00f4mero levorrotat\u00f3rio (3R) \u00e9 a forma biologicamente ativa respons\u00e1vel pelo transporte de \u00e1cidos graxos de cadeia longa mitocondrial via sistema carnitina palmitoiltransferase (CPT-I \/ CPT-II); biosintetizado endogenamente a partir de L-lisina e L-metionina; tamb\u00e9m chamado de levocarnitina (INN) ou Vitamina B<sub>T<\/sub> em literatura mais antiga<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>7<\/sub>H<sub>15<\/sub>N\u00c3O<sub>3<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">161.20 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome IUPAC<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">(3R)-3-Hidroxi-4-(trimetilaz\u00e2nio)butanoato<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (derivado de amino\u00e1cido de pequena mol\u00e9cula \u2014 n\u00e3o \u00e9 um pept\u00eddeo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado, branco a branco-amarelado (forma zwitteri\u00f4nica \/ sal interno)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, use dentro de ~30 dias. Proteger da luz. Evite ciclos repetidos de congelamento-descongelamento da solu\u00e7\u00e3o reconstitu\u00edda. A levocarnitina \u00e9 higrosc\u00f3pica \u2014 feche os frascos imediatamente ap\u00f3s cada retirada.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Altamente sol\u00favel em \u00e1gua (zwitteri\u00e3o em pH fisiol\u00f3gico). Reconstitui-se rapidamente em \u00e1gua bacteriost\u00e1tica ou \u00e1gua est\u00e9ril com agita\u00e7\u00e3o suave. N\u00e3o s\u00e3o necess\u00e1rios solventes especializados. Solu\u00e7\u00f5es de trabalho podem ser preparadas em concentra\u00e7\u00f5es de at\u00e9 ~500 mg\/mL sem precipita\u00e7\u00e3o.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 L-Carnitina?<\/h2>\n<p><strong>L-Carnitina<\/strong> (levocarnitina) \u00e9 um pequeno derivado de amino\u00e1cido quatern\u00e1rio de am\u00f4nio, sol\u00favel em \u00e1gua, com a f\u00f3rmula molecular C<sub>7<\/sub>H<sub>15<\/sub>N\u00c3O<sub>3<\/sub> e peso molecular 161,20 g\/mol. \u00c9 <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em> \u2014 it is a single-residue zwitterionic molecule derived metabolically from the amino acids L-lysine and L-methionine through a multistep biosynthetic pathway distributed across kidney, liver, and brain. Only the (3R) enantiomer (the L-form \/ levo form \/ levocarnitine) is biologically active; the (3S) enantiomer (D-carnitine) is inactive and is now well-documented to interfere with the L-form&#8217;s transport, which is why pharmaceutical-grade material is supplied as the enantiomerically pure L-form rather than as racemic DL-carnitine. The molecule&#8217;s central physiological function is to serve as the <strong>transportador obrigat\u00f3rio<\/strong> para transportar \u00e1cidos graxos de cadeia longa (C<sub>12<\/sub>+) across the otherwise-impermeable mitochondrial inner membrane, where they are subsequently broken down by \u03b2-oxidation to acetyl-CoA, the substrate for the citric acid cycle and ATP synthesis. The transport machinery \u2014 carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane, the carnitine\/acylcarnitine translocase (CACT) across the inner membrane, and carnitine palmitoyltransferase II (CPT-II) on the matrix side \u2014 converts free fatty acids into acylcarnitines, ferries them across the bilayer, and releases them again as acyl-CoAs for oxidation. L-Carnitine is therefore the rate-limiting metabolite for fat oxidation in tissues with high oxidative demand: skeletal muscle, cardiac muscle, and liver. L-Carnitine is also a high-affinity buffer of the cellular acyl-CoA \/ free-CoA ratio. By accepting acyl groups onto its hydroxyl side chain, L-carnitine maintains the intracellular pool of free CoA that other CoA-dependent enzymes (pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, fatty-acid \u03b2-oxidation) require to function. Carnitine deficiency therefore produces effects beyond fat oxidation alone \u2014 propagating into pyruvate handling, TCA-cycle flux, and overall mitochondrial bioenergetic balance. L-Carnitine has FDA approval (under the name <em>levocarnitina<\/em>) para uso terap\u00eautico humano em <strong>defici\u00eancia prim\u00e1ria e secund\u00e1ria de carnitina<\/strong> (oral and IV formulations) and is widely used in contexts that examine mitochondrial bioenergetics, fat oxidation, insulin sensitivity, cardiovascular function, neuroprotection, exercise physiology, and sperm motility. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Transporte Mitocondrial de \u00c1cidos Graxos de Cadeia Longa<\/h2>\n<p>L-Carnitine&#8217;s central mechanism is documented across several decades of mitochondrial biochemistry studies:<\/p>\n<ul>\n<li><strong>Carnitina palmitoiltransferase I (CPT-I) \u2014 membrana mitocondrial externa<\/strong> \u2014 Os \u00e1cidos graxos de cadeia longa primeiro s\u00e3o ativados para acil-CoA de cadeia longa no citoplasma. A CPT-I, inserida na membrana mitocondrial externa, transfere o grupo acil da CoA para o hidroxil da L-carnitina, gerando acilcarnitina de cadeia longa. Este \u00e9 o passo comprometido e mais rigidamente regulado da oxida\u00e7\u00e3o mitocondrial de gorduras \u2014 a CPT-I \u00e9 alostericamente inibida pelo malonil-CoA (o produto da acetil-CoA carboxilase no metabolismo lipog\u00eanico em estado alimentado), que \u00e9 como a insulina\/glucagon e o sistema AMPK regulam a oxida\u00e7\u00e3o de gorduras contra a s\u00edntese de gorduras.<\/li>\n<li><strong>Carnitina\/acilcarnitina translocase (CACT) \u2014 membrana mitocondrial interna<\/strong> \u2014 A acilcarnitina de cadeia longa gerada pela CPT-I n\u00e3o pode difundir atrav\u00e9s da membrana mitocondrial interna. A CACT, um antiportador, troca acilcarnitina citos\u00f3lica por carnitina livre na matriz em uma estequiometria 1:1, entregando acilcarnitina na matriz e reciclando carnitina para novos ciclos da CPT-I.<\/li>\n<li><strong>Carnitina palmitoiltransferase II (CPT-II) \u2014 membrana mitocondrial interna, voltada para a matriz<\/strong> \u2014 Na matriz, a CPT-II reverte a rea\u00e7\u00e3o da CPT-I: transfere o grupo acil da carnitina de volta para a CoA da matriz, regenerando acil-CoA de cadeia longa, que agora pode entrar na \u03b2-oxida\u00e7\u00e3o. A carnitina livre liberada \u00e9 retornada atrav\u00e9s da membrana via CACT para outro ciclo de transporte.<\/li>\n<li><strong>Tamponamento da raz\u00e3o acil-CoA\/CoA livre e flexibilidade metab\u00f3lica<\/strong> \u2014 Al\u00e9m do transporte de cadeia longa, a L-carnitina aceita grupos acila de cadeia curta e m\u00e9dia (acetilcarnitina, propionilcarnitina) e atua como um tamp\u00e3o de alta capacidade da rela\u00e7\u00e3o acil-CoA\/CoA livre intracelular. Isso mant\u00e9m a CoA livre para a piruvato desidrogenase, \u03b1-cetoglutarato desidrogenase e \u03b2-oxida\u00e7\u00e3o. A gera\u00e7\u00e3o de acetilcarnitina tamb\u00e9m serve como o mecanismo pelo qual o excesso de acetil-CoA \u2014 proveniente do jejum, cetog\u00eanese ou exerc\u00edcio \u2014 pode ser tamponado e exportado com seguran\u00e7a atrav\u00e9s da membrana mitocondrial.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of orally-administered L-carnitine is unusual: oral bioavailability is low (~15%) due to active intestinal saturation, with the remaining 85% subject to extensive bacterial degradation in the colon (yielding TMA and TMAO \u2014 a finding that has attracted attention in cardiovascular studies). Intravenous and intramuscular administration routes achieve much higher plasma levels and bypass the gut-microbial degradation pathway entirely, which is why pharmacological protocols commonly use parenteral administration despite the convenience of oral dosing. <\/p>\n<h2>Published Evidence<\/h2>\n<p>L-Carnitine is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Fun\u00e7\u00e3o mitocondrial e bioenerg\u00e9tica<\/strong> \u2014 Respirometria Seahorse\/Oroboros, potencial de membrana mitocondrial, taxa de gera\u00e7\u00e3o de ATP, taxa de oxida\u00e7\u00e3o de \u00e1cidos graxos em culturas de hepat\u00f3citos prim\u00e1rios, m\u00fasculo esquel\u00e9tico e cardiomi\u00f3citos<\/li>\n<li><strong>Oxida\u00e7\u00e3o de gordura e flexibilidade metab\u00f3lica<\/strong> \u2014 altern\u00e2ncia entre oxida\u00e7\u00e3o de glicose e gordura no m\u00fasculo esquel\u00e9tico e f\u00edgado; modelos de revers\u00e3o de resist\u00eancia \u00e0 insulina; coortes de estudo em roedores obesos e DIO<\/li>\n<li><strong>Insulin sensitivity studies<\/strong> \u2014 improvement in skeletal-muscle insulin sensitivity in models of metabolic syndrome and type 2 diabetes preclinical studies; mechanistic dissection of the L-carnitine \/ acyl-CoA buffering \/ pyruvate handling axis<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 angina, heart failure, ischemia-reperfusion injury, cardiomyopathy (in particular doxorubicin-induced cardiotoxicity and primary carnitine-deficiency cardiomyopathy); TMA\/TMAO microbiome-axis cardiovascular studies<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 Alzheimer-disease in-vitro models (acetylcarnitine specifically), Parkinson-disease models, peripheral diabetic neuropathy preclinical models, autism-spectrum studies where carnitine deficiency has been implicated<\/li>\n<li><strong>Sperm motility and male fertility studies<\/strong> \u2014 epididymal acquisition of motility, mitochondrial energetics of sperm flagellar beat, antioxidant protection of spermatozoa; one of the most-studied compounds in male-fertility studies<\/li>\n<li><strong>Exercise physiology and endurance studies<\/strong> \u2014 substrate utilisation during prolonged exercise, glycogen sparing, post-exercise recovery; studies interest in carnitine loading protocols and insulin co-administration to overcome muscle-uptake saturation<\/li>\n<li><strong>Chronic kidney disease \/ haemodialysis studies<\/strong> \u2014 carnitine deficiency is common in dialysis-dependent end-stage renal disease patients and L-carnitine has FDA approval for this indication; preclinical studies continues on dialysis-related cardiomyopathy and muscle weakness<\/li>\n<\/ul>\n<p>For broader context on mitochondrial and metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> (coenzima dinucleot\u00eddica oxidada, substrato central do transporte de el\u00e9trons), <a href=\"https:\/\/medsbase.com\/pt-br\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (pept\u00eddeo ligante de cardiolipina direcionado \u00e0 mitoc\u00f4ndria), e <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo regulador metab\u00f3lico derivado de mitoc\u00f4ndria). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">peptides &amp; compounds catalog<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks L-Carnitine in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>600 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 dose-titration protocols, in-vitro mitochondrial-function panels, short-cycle in-vivo work, sperm-motility studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1200 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle or higher-dose protocols \u2014 long-arm metabolic studies, exercise-physiology saturation experiments, multi-cohort work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized levocarnitine zwitterion, \u226599% HPLC purity). Vial doses are deliberately much larger than the peptide range (5\u201320 mg) because L-carnitine is a small molecule used at gram-level doses \u2014 a 600 mg or 1200 mg vial corresponds roughly to a single intravenous dose in rodent or large-animal protocols. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Comparar \u2014 L-Carnitina vs NAD\u207a<\/h2>\n<p>L-Carnitina e <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> are the two non-peptide mitochondrial \/ metabolic support compounds in this catalogue, and they target completely different layers of mitochondrial bioenergetics. L-Carnitine sits on the <em>lado do combust\u00edvel<\/em> \u2014 ela transporta \u00e1cidos graxos de cadeia longa para a matriz para \u03b2-oxida\u00e7\u00e3o. O NAD\u207a est\u00e1 no <em>lado do transporte de el\u00e9trons<\/em> \u2014 it is the obligate electron acceptor for \u03b2-oxidation, glycolysis, and the TCA cycle, regenerated by Complex I of the electron transport chain. The two compounds are mechanistically complementary, and protocols sometimes combine them to probe upstream-substrate vs downstream-electron-flux contributions to mitochondrial output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">L-Carnitina<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD\u207a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de amino\u00e1cido quatern\u00e1rio de am\u00f4nio (zwitterion \u00fanico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coenzima dinucleot\u00eddica (nucleot\u00eddeos de adenina + nicotinamida unidos via difosfato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">161.20 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663,43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Papel nas mitoc\u00f4ndrias<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Transportador \u2014 transporte de \u00e1cidos graxos de cadeia longa atrav\u00e9s da membrana interna<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aceitador de el\u00e9trons para \u03b2-oxida\u00e7\u00e3o, glic\u00f3lise, ciclo de TCA; substrato para sirtu\u00ednas e PARPs<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oxida\u00e7\u00e3o de gordura, sensibilidade \u00e0 insulina, cardiovascular, motilidade esperm\u00e1tica, fisiologia do exerc\u00edcio<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologia das sirtu\u00ednas, longevidade, envelhecimento celular, regula\u00e7\u00e3o redox do eixo NAD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Aprova\u00e7\u00e3o da FDA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim \u2014 levocarnitina, para defici\u00eancia prim\u00e1ria\/secund\u00e1ria de carnitina (oral e intravenosa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Bioss\u00edntese end\u00f3gena<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A partir de L-lisina e L-metionina, nos rins\/f\u00edgado\/c\u00e9rebro<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A partir de triptofano (via de novo) ou nicotinamida\/niacina (via de salvamento)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estabilidade plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Est\u00e1vel \u2014 meia-vida de horas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Inst\u00e1vel \u2014 meia-vida de minutos curtos em solu\u00e7\u00e3o; oxida e degrada rapidamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Centenas de mg a n\u00edvel de gramas (dose \u00fanica em protocolos com roedores\/grandes animais)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dezenas a centenas de mg (cultura celular: concentra\u00e7\u00f5es em \u00b5M)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on long-chain fatty-acid oxidation, cardiovascular metabolic function, insulin sensitivity, or sperm motility, L-Carnitine is the canonical reference compound. For studies focused on sirtuin biology, longevity-axis biochemistry, or NAD-dependent redox regulation, <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> \u00e9 a ferramenta mais direcionada. Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-br\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin \/ inner-membrane-targeted mitochondrial studies and <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos fechados a \u221220 \u00b0C. A L-Carnitina liofilizada \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 36 meses e a \u221220 \u00b0C por at\u00e9 60 meses \u2014 substancialmente mais est\u00e1vel do que a maioria dos pept\u00eddeos liofilizados porque a estrutura de pequena mol\u00e9cula n\u00e3o possui liga\u00e7\u00f5es amida ou pontes dissulfeto para hidrolisar. O composto \u00e9, no entanto, <strong>higrosc\u00f3pico<\/strong>, portanto, feche os frascos imediatamente ap\u00f3s cada retirada e evite a exposi\u00e7\u00e3o prolongada \u00e0 umidade ambiente. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o comprimido liofilizado). Para um frasco de 600 mg, 3,0 mL de \u00e1gua bacteriost\u00e1tica rendem uma concentra\u00e7\u00e3o de trabalho de 200 mg\/mL; 1,2 mL rendem um estoque de 500 mg\/mL. Para um frasco de 1200 mg, 6,0 mL rendem um estoque de trabalho de 200 mg\/mL; 2,4 mL rendem um estoque de 500 mg\/mL. A L-Carnitina dissolve-se muito rapidamente com agita\u00e7\u00e3o suave \u2014 normalmente em 10\u201330 segundos \u2014 porque \u00e9 um pequeno zwitterion sem estrutura dobrada para perturbar. Uma vez reconstitu\u00eddo, armazene o frasco a 2\u20138 \u00b0C e use dentro de 30 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>A L-Carnitina \u00e9 um pept\u00eddeo?<\/h3>\n<p>N\u00e3o. A L-Carnitina \u00e9 um derivado de amino\u00e1cido quatern\u00e1rio de am\u00f4nio de pequena mol\u00e9cula (MW 161,20 g\/mol), <em>n\u00e3o<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> because it serves a complementary role in mitochondrial \/ metabolic support and is supplied in the same injectable vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre L-Carnitina e acetil-L-carnitina (ALCAR)?<\/h3>\n<p>Acetyl-L-carnitine is L-carnitine with an acetyl group esterified to the hydroxyl side chain. ALCAR crosses the blood-brain barrier more efficiently and is the form most commonly used in CNS-focused studies (Alzheimer-disease, peripheral neuropathy). The base L-carnitine zwitterion that we supply here is the form used in peripheral metabolic support (cardiovascular, skeletal muscle, sperm motility, dialysis-related deficiency). The two compounds interconvert metabolically through carnitine acetyltransferase. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre L-Carnitina e DL-carnitina rac\u00eamica?<\/h3>\n<p>Only the L (3R) enantiomer is biologically active. The D (3S) enantiomer is inactive and is now well-documented to interfere with L-form transport, accumulating in tissue and producing weakness and other adverse effects in long-term high-dose contexts. Pharmaceutical-grade levocarnitine (what we supply) is the enantiomerically pure L-form. The racemic DL-form is obsolete and is no longer used in either clinical or rigorous contexts. <\/p>\n<h3>Why is the dose so much larger than the peptide doses in this catalogue?<\/h3>\n<p>L-Carnitine is a small molecule (MW 161) and is used at gram-level doses \u2014 the body&#8217;s endogenous carnitine pool is approximately 25 g, concentrated in skeletal muscle. Study protocols typically use 100\u2013500 mg\/kg in rodent in-vivo work, which translates to hundreds of milligrams to grams per dose. Compare this to peptides (BPC-157, semaglutide, etc.) where typical doses are 100 \u00b5g to 5 mg per administration \u2014 three to four orders of magnitude smaller, reflecting the different molecular weights and the different receptor \/ mechanism scales. <\/p>\n<h3>What is the TMA \/ TMAO question I see in cardiovascular studies?<\/h3>\n<p>A subset of L-carnitine ingested orally is degraded by gut bacteria to trimethylamine (TMA), which the liver then oxidises to trimethylamine-N-oxide (TMAO). Elevated TMAO levels have been associated in epidemiological studies with adverse cardiovascular events, raising a controversy about whether long-term high-dose oral L-carnitine supplementation may be net-beneficial or net-harmful for cardiovascular endpoints. The question is active and unresolved. Parenteral L-carnitine bypasses the gut-microbial degradation pathway and is not subject to this concern. <\/p>\n<h3>What does CPT-I inhibition mean in metabolic support?<\/h3>\n<p>Carnitine palmitoyltransferase I (CPT-I) is the rate-limiting enzyme for mitochondrial long-chain fatty-acid uptake. Etomoxir is a classical CPT-I inhibitor used to block fat oxidation in study models; it is the pharmacological tool counterpart to the L-carnitine substrate. Study protocols sometimes combine L-carnitine supplementation (substrate side) with CPT-I inhibition (enzymatic side) to dissect substrate-limited vs enzyme-limited fat oxidation in different tissues and conditions. <\/p>\n<h3>Can I combine L-Carnitine with NAD\u207a in the same protocol?<\/h3>\n<p>Yes \u2014 the two compounds target different layers of mitochondrial bioenergetics (substrate transport vs electron transport), and combination is commonly used in studies that aims to probe upstream vs downstream limitations on mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. <\/p>\n<h3>What route of administration is used in published studies?<\/h3>\n<p>Intravenous and intramuscular routes are most common in pharmacological studies because they bypass the low (~15%) oral bioavailability and the gut-microbial TMA\/TMAO degradation pathway. Subcutaneous administration is used in some rodent protocols. Oral administration is used in pharmacokinetic and nutritional studies where the bioavailability question is itself the studies focus. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Transportador mitocondrial de \u00e1cidos graxos de cadeia longa (n\u00e3o \u00e9 um pept\u00eddeo)<br \/>\n\u2705 Substrato do mecanismo de transporte CPT-I \/ CACT \/ CPT-II<br \/>\n\u2705 Estudo em modelos de oxida\u00e7\u00e3o de gordura, sensibilidade \u00e0 insulina e cardiovasculares<br \/>\n\u2705 Acyl-CoA \/ free-CoA ratio buffer; sperm-motility studies<br \/>\n\u2705 Levocarnitina aprovada pela FDA para defici\u00eancia de carnitina (oral e intravenosa)<\/p>\n<p><strong>L-Carnitina<\/strong> cont\u00e9m levocarnitina sint\u00e9tica.<\/p>","protected":false},"featured_media":71414,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6472,6469,6470,6471],"class_list":["post-71409","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-amino-acid-derivative","product_tag-l-carnitine","product_tag-levocarnitine","product_tag-mitochondrial","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71414"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71409"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71409"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71409"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}